Key Takeaways: World EPA Congress 2022
Did you miss our presentation at this year’s World EPA Congress in Amsterdam? Precision experts Richard Macaulay (VP, Global Pricing and Market Access) and David Carr (Director, Global Pricing and Market Access) presented “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” which analyzes the access success of launched gene therapies and draws best-practice learnings for future gene therapies.
On-Demand Webinar: Planning for the Commercialization of Advanced Therapies
In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?
PRECISIONxtract Launches OncoGenius, Empowering Oncology Brands With New Insights From Provider-level Data
Recent acquisition of veteran pharmaceutical market consultancy Oncology Reimbursement Management propels and further elevates Precision’s oncology commercialization solutions.
Conference: Gene Therapy for Rare Disorders, 2022
Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.
White Paper: Considerations for the Clinical Development of Cell & Gene Therapies (Part 2: Gene Therapies)
Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.